AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17258855 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 62
Study 15197377 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation and training provided by nurse educators on best practice protocols for prevention of decline in activities of daily living, pain, and depression.
Number of subjects: 2
Study 14700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene cream 0.1%
Number of subjects: 31
Study 14700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 31
Study 14700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin formulations (Avita cream 0.025%, Retin‐A cream 0.025%, Retin‐A cream 0.05%, Retin‐A Micro gel 0.1%, and generic cream 0.025%)
Number of subjects: 31
Study 14700217 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum (negative control)
Number of subjects: 31
Study 10216903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led service for blood product support
Number of subjects: 45
Study 7605761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine (EPI) intravenous infusion
Number of subjects: 49
Study 7605761 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PHE) intravenous infusion
Number of subjects: 49
Study 2194537 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of radiotherapy
Number of subjects: 0
Study 2194537 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of endocrine treatment
Number of subjects: 0
Study 2194537 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of cytostatic treatment
Number of subjects: 0
Study 2194537 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment
Number of subjects: 0
Study 85872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin added to glucose solution
Number of subjects: 21
Study 85872 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline (pharmacological inhibition of gastric emptying)
Number of subjects: 21
Study 85872 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum and pectin added to paracetamol
Number of subjects: 21
Study 85872 — intervention group
Group type: COMPARATOR
Intervention: Control (without pectin or guar gum)
Number of subjects: 21
Study 31648210 — intervention group
Group type: EXPERIMENTAL
Intervention: Method employing geometric and dosimetric information for DVH prediction
Number of subjects: 106
Study 31648210 — intervention group
Group type: COMPARATOR
Intervention: Method utilizing only geometric information for DVH prediction
Number of subjects: 106
Study 31648210 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DVH prediction model using geometric and dosimetric information
Number of subjects: 106
Study 27817116 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tarsal strip technique
Number of subjects: 184
Study 27817116 — intervention group
Group type: COMPARATOR
Intervention: Conventional tarsal strip
Number of subjects: 184
Study 26543007 — intervention group
Group type: EXPERIMENTAL
Intervention: General Cognitive Training (CT)
Number of subjects: 2912
Study 26543007 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning Cognitive Training (CT)
Number of subjects: 2912
Study 23566948 — intervention group
Group type: EXPERIMENTAL
Intervention: 60° needle angle
Number of subjects: 19
Study 23566948 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° needle angle
Number of subjects: 19
Study 23566948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≤ 25
Number of subjects: 19
Study 23566948 — intervention group
Group type: COMPARATOR
Intervention: Reactogenicity
Number of subjects: 19
Study 21447136 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (group I)
Number of subjects: 102
Study 21447136 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group U)
Number of subjects: 102
Study 19622755 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 27
Study 17593884 — intervention group
Group type: EXPERIMENTAL
Intervention: Family expressed emotion (EE) components: rejection, warmth, protectiveness, and fusion in established disorder samples.
Number of subjects: 0
Study 17593884 — intervention group
Group type: EXPERIMENTAL
Intervention: Family expressed emotion (EE) components in mothers.
Number of subjects: 0
Study 17593884 — intervention group
Group type: EXPERIMENTAL
Intervention: Family expressed emotion (EE) components in fathers.
Number of subjects: 0
Study 15198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational hypertension
Number of subjects: 80
Study 15198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia
Number of subjects: 80
Study 15198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia with HELLP syndrome
Number of subjects: 80
Study 15198784 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive women)
Number of subjects: 80
Study 11465516 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 200 mg, weekly intramuscular injections
Number of subjects: 32
Study 11465516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame seed oil)
Number of subjects: 32
Study 9709876 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐TV
Number of subjects: 2398
Study 9709876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2398
Study 31228026 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced PMTCT Intervention (EI) - three group and three individual intervention sessions
Number of subjects: 683
Study 31228026 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 683
Study 31228026 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced PMTCT Intervention (EI)
Number of subjects: 683
Study 28393669 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A + serial casting
Number of subjects: 80
Study 28393669 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A only
Number of subjects: 80
Study 25528430 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin + laropiprant (ERN/LPR)
Number of subjects: 30
Study 25528430 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate (FFB)
Number of subjects: 30
Study 25528430 — intervention group
Group type: COMPARATOR
Intervention: nondiabetic patients with normal HDL
Number of subjects: 30
Study 23281132 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg Bacopa monnieri (BM)
Number of subjects: 24
Study 23281132 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 mg Bacopa monnieri (BM)
Number of subjects: 24
Study 23281132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19217460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pravastatin (10 mg/d)
Number of subjects: 21
Study 19217460 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pravastatin (40 mg/d)
Number of subjects: 21
Study 19217460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 21
Study 17313292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic strength training (BST)
Number of subjects: 33
Study 17313292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT)
Number of subjects: 33
Study 17313292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 15196159 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole daily
Number of subjects: 53
Study 15196159 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg itraconazole daily
Number of subjects: 53
Study 15196159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12068841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine 2 mg
Number of subjects: 0
Study 12068841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine 3 mg
Number of subjects: 0
Study 12068841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (general)
Number of subjects: 0
Study 12068841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine
Number of subjects: 0
Study 12068841 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0
Study 9793702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray (20 mg/dose)
Number of subjects: 26
Study 9793702 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of sumatriptan
Number of subjects: 26
Study 7620630 — intervention group
Group type: EXPERIMENTAL
Intervention: Laufband therapy (LB) with body weight support (BWS) and assisted limb movements
Number of subjects: 89
Study 7620630 — intervention group
Group type: EXPERIMENTAL
Intervention: Laufband therapy (LB)
Number of subjects: 89
Study 7620630 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 89
Study 2515583 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-Roferon (R-IFN) applied as ointment, 20,000 IU/g
Number of subjects: 0
Study 2515583 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-Ginterferon (G-IFN) applied as ointment, 10,000 IU/g
Number of subjects: 0
Study 2515583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both R-IFN and G-IFN
Number of subjects: 0
Study 341943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (GB‐94)
Number of subjects: 0
Study 341943 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 341943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31765640 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo plus education only
Number of subjects: 0
Study 31765640 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide plus education only
Number of subjects: 0
Study 31765640 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo plus biofeedback
Number of subjects: 0
Study 31765640 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide plus biofeedback
Number of subjects: 0
Study 31765640 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to fecal incontinence treatment
Number of subjects: 0
Study 30704287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg od plus a P2Y12 inhibitor (group 1)
Number of subjects: 2124
Study 30704287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (group 2)
Number of subjects: 2124
Study 30704287 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus dual antiplatelet therapy (group 3)
Number of subjects: 2124
Study 27531675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 2011
Study 27531675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 2011
Study 27531675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose (150-600 mg/d)
Number of subjects: 2011
Study 27531675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2011
Study 25564832 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-based breast self-exam (BSE)/testicular self-exam (TSE) training
Number of subjects: 1058
Study 24399120 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg for 15 days + Serenoa repens extract for 8 weeks
Number of subjects: 56
Study 24399120 — intervention group
Group type: COMPARATOR
Intervention: Prulifloxacin 600 mg for 15 days
Number of subjects: 56
Study 21871782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 500mg three times daily for 2 days, then oral amoxicillin for 3 more days
Number of subjects: 42
Study 21871782 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ampicillin 1g four times daily for 2 days, then oral amoxicillin for 3 more days
Number of subjects: 42
Study 18826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-fat)
Number of subjects: 55
Study 18826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (high-fat)
Number of subjects: 55
Study 18826492 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate low-fat diet
Number of subjects: 55
Study 17599747 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (10 mg bipuvicaine, 40 mg triamcinolone hexacetonide)
Number of subjects: 52
Study 17599747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mg bipuvicaine, 2 ml saline)
Number of subjects: 52
Study 17599747 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 52
Study 15889559 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 70
Study 15889559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 70
Study 11593094 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (with possible additional medications: ACE-inhibitor, beta-blocker, diuretic)
Number of subjects: 347
Study 11593094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 11593094 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 347
Study 9869994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar mode at atrial sensitivities of 0.625‐1.50 mV
Number of subjects: 34
Study 9869994 — intervention group
Group type: COMPARATOR
Intervention: Bipolar mode at atrial sensitivities of 0.625‐1.50 mV
Number of subjects: 34
Study 9869994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar mode at sensitivities of > 1.50 mV
Number of subjects: 34
Study 9869994 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal sensitivity settings for unipolar leads during AECG monitoring
Number of subjects: 34
Study 9869994 — intervention group
Group type: COMPARATOR
Intervention: Bipolar mode during AECG monitoring
Number of subjects: 34
Study 9869994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar mode for atrial leads
Number of subjects: 34
Study 9869994 — intervention group
Group type: COMPARATOR
Intervention: Bipolar mode for atrial leads
Number of subjects: 34
Study 9869994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar mode for ventricular leads
Number of subjects: 34
Study 8017036 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Relaxation Therapy (PRT)
Number of subjects: 124
Study 8017036 — intervention group
Group type: COMPARATOR
Intervention: No Psychological Relaxation Therapy (Control)
Number of subjects: 124
Study 8017036 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Number of subjects: 124
Study 2542629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily) with flunarizine (10 mg daily)
Number of subjects: 40
Study 2542629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30039986 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg·kg-1
Number of subjects: 22
Study 28517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT) with prompt revascularization
Number of subjects: 2368
Study 28517955 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT) alone
Number of subjects: 2368
Study 28517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2368
Study 28517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2368
Study 28517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 2368
Study 28517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and former smokers
Number of subjects: 2368
Study 25376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss impregnated with 5% chlorhexidine gluconate, used twice a day for 15 days
Number of subjects: 30
Study 25376536 — intervention group
Group type: COMPARATOR
Intervention: Waxed floss without impregnation, used twice a day for 15 days
Number of subjects: 30
Study 25376536 — intervention group
Group type: COMPARATOR
Intervention: No interproximal cleaning (negative control)
Number of subjects: 30
Study 23392665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus ears (n = 124)
Number of subjects: 230
Study 23392665 — intervention group
Group type: COMPARATOR
Intervention: Non-tinnitus ears (n = 106)
Number of subjects: 230
Study 21324888 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30.0-39.9 kg/m² (minimally adjusted model)
Number of subjects: 6082
Study 21324888 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30.0-39.9 kg/m² (maximally adjusted model)
Number of subjects: 6082
Study 21324888 — intervention group
Group type: COMPARATOR
Intervention: BMI 25-27.4 kg/m² (referent group)
Number of subjects: 6082
Study 19454860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose LRPT 40 mg/d for 12 days with coadministered single-dose warfarin 30 mg
Number of subjects: 13
Study 19454860 — intervention group
Group type: COMPARATOR
Intervention: Single-dose warfarin 30 mg alone
Number of subjects: 13
Study 17678656 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT (constraint‐induced movement therapy)
Number of subjects: 47
Study 17678656 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention (control treatment)
Number of subjects: 47
Study 15201103 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ultrasound therapy
Number of subjects: 68
Study 15201103 — intervention group
Group type: COMPARATOR
Intervention: Ultra short‐wave electrotherapy
Number of subjects: 68
Study 12759515 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day plus acenocoumarol at a targeted INR of 2.4‐3.6
Number of subjects: 121
Study 12759515 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol alone at the same dosage
Number of subjects: 121
Study 9523210 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewish women with familial ovarian cancer
Number of subjects: 471
Study 9523210 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewish women with a first-degree relative with ovarian cancer
Number of subjects: 471
Study 9523210 — intervention group
Group type: COMPARATOR
Intervention: Non-Jewish women with a first-degree relative with ovarian cancer
Number of subjects: 471
Study 9523210 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewish women with no first-degree relative with ovarian cancer
Number of subjects: 471
Study 7907073 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 MU 3 times weekly for 6 months)
Number of subjects: 108
Study 7907073 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (12-month course: 3 MU 3 times weekly for the first 6 months, 2 MU for the following 3 months, and 1 MU for the last 3 months)
Number of subjects: 108
Study 7907073 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (both regimens)
Number of subjects: 108
Study 2766862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cis-platinum (120 mg/m2) combined with cyclophosphamide (600 mg/m2)
Number of subjects: 0
Study 2766862 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cis-platinum (60 mg/m2) combined with cyclophosphamide (600 mg/m2)
Number of subjects: 0
Study 19348 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastropulgit Gel (liquid antacid)
Number of subjects: 0
Study 19348 — intervention group
Group type: COMPARATOR
Intervention: Salicylate alone
Number of subjects: 0
Study 29042358 — intervention group
Group type: EXPERIMENTAL
Intervention: INF/SB2
Number of subjects: 396
Study 29042358 — intervention group
Group type: EXPERIMENTAL
Intervention: INF/INF
Number of subjects: 396
Study 29042358 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2/SB2
Number of subjects: 396
Study 27172277 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH)
Number of subjects: 30
Study 27172277 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 30
Study 23169901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimentation (30% more PN macronutrients)
Number of subjects: 142
Study 23169901 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 142
Study 22445501 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1Ra)
Number of subjects: 0
Study 22445501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22445501 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Number of subjects: 0
Study 20628388 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 resin microspheres (median activity, 1.7 GBq; range, 0.9-2.2)
Number of subjects: 50
Study 20628388 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 resin microspheres
Number of subjects: 50
Study 18072006 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference support
Number of subjects: 0
Study 18072006 — intervention group
Group type: COMPARATOR
Intervention: Regular telephone support
Number of subjects: 0
Study 18072006 — intervention group
Group type: COMPARATOR
Intervention: Current clinic review follow-up
Number of subjects: 0
Study 16182635 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM dietary recall
Number of subjects: 80
Study 16182635 — intervention group
Group type: COMPARATOR
Intervention: Interview-administered dietary recall (FIAS)
Number of subjects: 80
Study 16182635 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized portion sizes
Number of subjects: 80
Study 15828162 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial enrolment
Number of subjects: 0
Study 10524635 — intervention group
Group type: COMPARATOR
Intervention: Glycyrrhizin (group G)
Number of subjects: 170
Study 10524635 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin plus ursodeoxycholic acid (group G+U)
Number of subjects: 170
Study 8624427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF)
Number of subjects: 69
Study 2041929 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with suspected acute myocardial infarction (MI)
Number of subjects: 397
Study 7014277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxatomide b.i.d.
Number of subjects: 35
Study 7014277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31300248 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (NaOCl)
Number of subjects: 52
Study 31300248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 52